AB051. P-19. A phase II study of infigratinib (BGJ398) in previously-treated advanced cholangiocarcinoma containing FGFR2 fusions

BACKGROUND: Fibroblast growth factor receptor 2 (FGFR2) fusions occur in 13–17% of intrahepatic cholangiocarcinomas (IHC). A multicenter, open-label, phase II study (NCT02150967) evaluated the antitumor activity of infigratinib, an ATP-competitive FGFR1–3-selective oral tyrosine kinase inhibitor, in...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Hepatobiliary Surg Nutr
Main Authors: Javle, Milind, Kelley, R. Kate, Roychowdhury, Sameek, Weiss, Karl Heinz, Abou-Alfa, Ghassan K., Macarulla, Teresa, Sadeghi, Saeed, Waldschmidt, Dirk, Zhu, Andrew X., Goyal, Lipika, Borad, Mitesh, Yong, Wei Peng, Borbath, Ivan, El-Khoueiry, Anthony, Philip, Philip, Moran, Susan, Ye, Yining, Ising, Mary, Lewis, Nancy, Bekaii-Saab, Tanios
Formato: Artigo
Idioma:Inglês
Publicado: AME Publishing Company 2019
Assuntos:
Poster Abstracts
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6421211/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/hbsn.2019.AB051
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares